Rodman & Renshaw Annual Global Investment Conference NYC Presenter Profiles

NEW YORK--(BUSINESS WIRE)--The Rodman & Renshaw Annual Global Investment Conference NYC takes place Sept. 13- 15, 2010 at the New York Palace Hotel in New York City.

“10 IT Companies to Watch in 2010”

Business Wire is a supporting sponsor for the Conference. Breaking news releases, IR Kits, and webcast advisories are available at TradeshowNews.com, Business Wire's trade show, conference, and event news resource.

Listed below are Rodman & Renshaw Annual Global Investment Conference NYC presenter profiles.

Company:	Advanced Cell Technology, Inc.
Ticker Symbol & Exchange:	OTCBB: ACTC
Investor Relations Contact:	Dan Schustack
Investor Relations Contact Phone:	212-732-4300
Web:	http://www.advancedcell.com
Date of Presentation:	13-Sep-10
Advanced Cell Technology (ACTC.OB), is a biotechnology company developing cellular therapies for the treatment of diseases that impact millions of people worldwide.
Helmed by Chairman/CEO William M. Caldwell IV, ACTC is commercializing its "RPE" therapy for retinal disease; recent milestones: Filed IND; NIH proposed revised definition of hESCs for funding; FDA granted "Orphan" status; secured broad patent; filed requested documentation with FDA for Phase I/II trial.
ACTC is also focused on its (Phase II-approved) Myoblast stem cell therapy for heart conditions as well as its Hemangioblast (HG) platform for the treatment of blood and cardiovascular diseases.
More information: http://www.advancedcell.com.
Company:	Aethlon Medical, Inc.
Ticker Symbol & Exchange:	OTCBB: AEMD
Investor Relations Contact:	John P. Salvador
Investor Relations Contact Phone:	[phone] x 307
Web:	www.aethlonmedical.com
Date of Presentation:	September 14, 2010 at 3:40 pm EDT
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the circulatory system. Our Hemopurifier® also captures tumor-secreted exosomes that suppress the immune system. Therapeutic strategies that directly inhibit or reverse the immunosuppressive destruction caused by exosomes do not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Company:	Allon Therapeutics Inc.
Ticker Symbol & Exchange:	TSX:NPC
Investor Relations Contact:	Aaron Keay
Investor Relations Contact Phone:	[phone]
Web:	www.allontherapeutics.com
Date of Presentation:	Tuesday, September 14, 2010
Allon Therapeutics Inc. is a clinical-stage biotechnology company focused on developing the first drugs that impact the progression of neurodegenerative diseases. Allon’s lead drug davunetide has demonstrated human efficacy in amnestic mild cognitive impairment, a precursor to Alzheimer’s disease, and cognitive impairment associated schizophrenia. Allon is proceeding in advanced clinical trials in an orphan indication, progressive supranuclear palsy (PSP), and will pursue the major markets, Alzheimer’s disease and cognitive impairment associated schizophrenia, with a pharmaceutical partner. The Company is listed on the Toronto Stock Exchange under the trading symbol “NPC” (Neuro Protection Company™) and based in Vancouver.
Company:	Allot Communications Ltd.
Ticker Symbol & Exchange:	NASDAQ: ALLT
Investor Relations Contact:	Jay Kalish, Executive Director
Investor Relations Contact Phone:	972-54-2211365
Web:	www.allot.com
Date of Presentation:	13-Sep
Allot is a leading supplier of service optimization and revenue generation solutions for fixed and mobile broadband service providers worldwide. Allot's rich portfolio of solutions transform broadband pipes into smart networks that can rapidly and efficiently deploy value added Internet services. Allot's scalable, carrier-grade solutions provide the visibility, topology awareness, security, application control and subscriber management that are vital to managing Internet service delivery, enhancing user experience, containing operating costs, and maximizing revenue in broadband networks.
Company:	Anavex Life Sciences Corp.
Ticker Symbol & Exchange:	OTC BB: AVXL
Investor Relations Contact:	Primoris Group Inc.
Investor Relations Contact Phone:	416-489-0092 or 1-866-505-2895
Web:	www.anavex.com
Date of Presentation:	Monday, September 13, 2010
Dr. Cameron Durrant, Executive Chairman of Anavex Life Sciences Corp., will be presenting at the Rodman & Renshaw Healthcare Conference at 4:45 pm ET on September 13, 2010 in New York City. He will discuss ANAVEX 2-73, the company’s first-of-a-new-class, oral, lead compound for the treatment of Alzheimer’s disease, which is entering Phase I/IIa clinical trials. Journalists and analysts alike are invited to contact us ([e-mail]) to schedule a meeting.
Anavex is a biopharmaceutical company engaged in the discovery and development of novel drug candidates for the treatment of neurological diseases and cancer. The company's proprietary SIGMACEPTOR™ Discovery Platform involves the rational design of drug compounds that are targeted to specific receptors involved in the modulation of multiple cellular biochemical signaling pathways.
Company:	Avantair Inc.
Ticker Symbol & Exchange:	OTCBB: AAIR
Investor Relations Contact:	Brandi Floberg
Investor Relations Contact Phone:	212-481-2050
Web:	www.avantair.com
Date of Presentation:	9/14/2010
Avantair, the only publicly traded stand-alone private aircraft operator and the sole North American provider of fractional shares, flight time cards and Axis Club Membership in the Piaggio Avanti aircraft, is headquartered in Clearwater, FL, with approximately 450 employees. The Company offers private travel solutions for individuals and businesses traveling within its service area, which includes the continental United States, Canada, the Caribbean and Mexico, at a fraction of the cost of whole aircraft ownership. The Company currently manages a fleet of 55 aircraft, with another 53 Piaggio Avanti aircraft on order through 2013. For more information about Avantair, please visit: www.avantair.com.
Company:	China GengSheng Minerals
Ticker Symbol & Exchange:	AMEX: CHGS
Investor Relations Contact:	Lee Roth
Investor Relations Contact Phone:	212-481-2050
Web:	www.thefigi.com
Date of Presentation:	9/14/2010
China GengSheng Minerals, Inc. ("GengSheng") develops, manufactures and markets a broad range of high-tech industrial material products, including monolithic refractories, industrial ceramics and fracture proppants. A market leader offering customized solutions, GengSheng sells its products primarily to the iron-and-steel industry as heat-resistant components for steel-making furnaces, industrial kilns and other high-temperature vessels to guarantee and improve the productivity of those expensive pieces of equipment while reducing their consumption of energy. Founded in 1986 and based in China's Henan province, GengSheng currently has over 200 customers in the iron, steel, oil, glass, cement, aluminum and chemical businesses located in China and other countries. For more information, please visit www.gengsheng.com.
Company:	China Valves Technology
Ticker Symbol & Exchange:	CVVT
Investor Relations Contact:	Ray Chen
Investor Relations Contact Phone:	86-13925279478
Web:	www.cvalve.com
Date of Presentation:	Sep. 13th, 2010
China Valves Technology, Inc. through its subsidiaries, Zhengzhou Zhengdie Valve Co, Ltd., Henan Kaifeng High Pressure Valve Co., Ltd., Tai Zhou Taide Valve Co., Ltd., Yangzhou Rock Valve Lock Technology Co., Ltd., Able Delight (Changsha) Valve Co., Ltd. and Shanghai Pudong Hanwei Valve Co., Ltd., is engaged in the development, manufacturing and sale of high-quality metal valves for the electricity, petroleum, chemical, water, gas and metallurgy industries. The Company has one of the best known brand names in China's valve industry, and its history can be traced back to 1959 when it was formed as a state-owned enterprise. The Company develops valve products through extensive research and development and owns a number of patents. It enjoys significant domestic market share and exports to Asia and Europe. For more information, visit website.
Company:	Colony Financial, Inc.
Ticker Symbol & Exchange:	NYSE: CLNY
Investor Relations Contact:	Andrew Blazier
Investor Relations Contact Phone:	[phone]
Web:	www.colonyfinancial.com
Date of Presentation:	9/14/2010
Colony Financial is a real estate finance and investment company that is focused primarily on acquiring and originating commercial real estate loans and real estate-related debt at attractive risk-adjusted returns. Secondary debt purchases may include performing, sub-performing or non-performing loans (including loan-to-own strategies). Colony Financial intends to elect and qualify to be taxed as a real estate investment trust, or REIT, for U.S. federal income tax purposes. Colony Financial is a component of the Russell 2000® and the Russell 3000® indices. For more information, visit www.colonyfinancial.com.
Company:	Cortex Pharmaceuticals, Inc.
Ticker Symbol & Exchange:	CORX.OB
Investor Relations Contact:	Erica Moran, IRG, New York
Investor Relations Contact Phone:	212-825-3210
Web:	www.cortexpharm.com
Date of Presentation:	Monday, September 13th, 2010
Cortex Pharmaceuticals is a neuroscience company focused on the discovery, development and commercialization of novel drug therapies for the treatment of neurological and psychiatric disorders. Cortex’s primary technology platform is a class of molecules called AMPAKINE® compounds, which are positive allosteric modulators of the AMPA-type glutamate receptor complex. AMPA receptors are expressed on the vast majority of neurons in the brain and mediate fast excitatory neurotransmission. By selectively increasing the activity of AMPA receptors, AMPAKINE molecules improve communication within neuronal networks, and have the potential for treating a wide range of central nervous system disorders, including Alzheimer’s disease, schizophrenia, depression, Huntington’s disease, Parkinson’s disease, recovery from stroke, ADHD and sleep apnea.
Company:	CryoPort, Inc
Ticker Symbol & Exchange:	OTCBB: CYRX
Investor Relations Contact:	LIPPERT/HEILSHORN & ASSOC
Investor Relations Contact Phone:	1 [phone]
Web:	www.CryoPort.com
Date of Presentation:	9/13/2010
CryoPort has developed a proprietary, technology-driven packaging and transportation system providing a “game changing” solution for the life sciences global frozen shipping market. Today, frozen shipments are predominately made using dry ice, which requires frequent re-icing and is hazardous material. The CryoPort Express shipping system has 10+ day holding times, is based upon a "green" innovative LN2-vapor dry shipper with web-based CryoPortal™ ordering technology and international logistics. The Company has entered into strategic relationships with FedEx and with DHL. The products developed by CryoPort, CryoPort Express® and CryoPortal™, are essential components for clinical trial specimens, diagnostics, and pharmaceutical products.
Company:	D. Medical Industries Ltd.
Ticker Symbol & Exchange:	DMED:NASDAQ
Investor Relations Contact:	Stephen Kilmer
Investor Relations Contact Phone:	T: [phone] C: [phone]
Web:	www.dmedicalindustries.com
Date of Presentation:	14-Sep-10
D. Medical is engaged through its subsidiaries in the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery. D. Medical has developed durable and semi-disposable insulin pumps, which continuously infuse insulin into a patient's body, using its proprietary spring-based delivery technology. D. Medical believes that its spring-based delivery mechanism is cost-effective compared to the motor and gear train mechanisms that drive competitive insulin pumps and also allows it to incorporate certain advantageous functions and design features in its insulin pumps. D. Medical has also developed a universal infusion set for insulin pumps and is focusing its R&D efforts on the development of a device that will combine a continuous glucose monitoring system and an insulin pump on the same patch.
Company:	Fortress International Group, Inc.
Ticker Symbol & Exchange:	Pink Sheets: FIGI
Investor Relations Contact:	Lee Roth
Investor Relations Contact Phone:	212-481-2050
Web:	www.thefigi.com
Date of Presentation:	9/15/2010
Fortress International Group, Inc. is leading mission-critical facilities into a new era of maximum uptime and efficiency. Fortress provides consulting and engineering, construction management and 24/7/365 site services for the world's most technology dependent organizations. Serving as a trusted advisor, Fortress delivers the strategic guidance and pre-planning that makes every stage of the critical facility lifecycle more efficient. For those who own, lease or manage mission-critical facilities, Fortress provides innovative end-to-end capital management, energy, IT strategy, procurement, design, construction, implementation and operations solutions that optimize performance and reduce cost.
For more information, visit: www.thefigi.com.
Company:	Helsinn Healthcare SA
Ticker Symbol & Exchange:	Private
Investor Relations Contact:	Riccardo Braglia
Investor Relations Contact Phone:	0041 (0) 91985 21 21
Web:	www.helsinn.com
Date of Presentation:	September 15th, 2010 12:05pm EDT
Helsinn Healthcare SA announced that Mr. Riccardo Braglia, CEO, will present an overview of the company, products and corporate goals at Rodman & Renshaw 12th Annual Healthcare Conference, New York, USA, on September 15th 2010 at 12:05pm EDT. The presentation will be webcast live and can be accessed through the web site (http://www.wsw.com/webcast/rrshq18/helsinn) (available for 90 days).
Helsinn (www.helsinn.com) is a privately owned Swiss-based pharmaceutical group with subsidiaries in USA and Ireland. Core business: oncology, supportive care and pain inflammation. Business strategy: in-license early stage new chemical entities, complete their development up to market approvals and out-license to its worldwide network of partners. Active pharmaceutical ingredients and drug products are manufactured at Helsinn's cGMP facilities.
Company:	InfuSystem Holdings, Inc.
Ticker Symbol & Exchange:	INHI: OCTBB
Investor Relations Contact:	Asher Dewhurst
Investor Relations Contact Phone:	[phone]
Web:	http://www.infusystem.com
Date of Presentation:	14-Sep-10
InfuSystem is the leading supplier of infusion services to oncologists and other outpatient treatment settings. The Company provides pole mounted and ambulatory pumps, supplies and related clinical, biomedical and billing services to practices and patients, nationwide. The Company's unique suite of services appeals to practices, patients and payors by improving access to clinically necessary medical equipment, while driving down costs and maximizing clinical outcomes.
Company:	Lihua International
Ticker Symbol & Exchange:	Nasdaq: LIWA
Investor Relations Contact:	Lee Roth
Investor Relations Contact Phone:	212-481-2050
Web:	www.lihuaintl.com
Date of Presentation:	9/14/2010
Lihua is a value-added manufacturer of copper replacement products for China's rapidly growing copper wire and copper replacement product market. Lihua is one of China’s first vertically integrated companies to develop, design and manufacture lower cost, high quality alternatives to pure copper magnet wire and pure copper alternative products. Lihua's current product offerings include CCA & copper wire, copper rod and copper anode. All products except CCA wire are produced from recycled scrap copper. Lihua's products are sold through distributors and direct to manufacturers in a wide variety of industries including consumer electronics, white goods, automotive, utility, telecommunications and specialty cable. Lihua's corporate and manufacturing headquarters are located in the heart of China's copper industry in Danyang, Jiangsu Province.
Company:	LJ International Inc.
Ticker Symbol & Exchange:	JADE
Investor Relations Contact:	Jennifer K. Zimmons
Investor Relations Contact Phone:	212-317-1400
Web:	www.ljintl.com
Date of Presentation:	9/13/10 - 4.55-5.20pm
LJ International Inc. (LJI) (NasdaqGM: JADE) is engaged in designing, branding, marketing and distribution of its full range of jewelry. LJI's global business is built on a vertical integration strategy and an unwavering commitment to quality and service. Through its China-based ENZO retail chain stores, LJI is now a major presence in China’s fast-growing retail jewelry market. As a wholesaler, it distributes to fine jewelers, department stores, national jewelry chains and electronic and specialty retailers throughout North America and Western Europe. Its product lines incorporate all major categories, including earrings, necklaces, pendants, rings and bracelets.
Company:	Metgasco Ltd
Ticker Symbol & Exchange:	MEL
Investor Relations Contact:	Glenda McLoughlin
Investor Relations Contact Phone:	02 9923 9100
Web:	www.metgasco.com.au
Date of Presentation:	15.09.10 at 2pm
Metgasco develops gas reserves and power for eastern Australian energy markets. The Company is active in the Clarence Moreton basin in NSW, exploring and developing coal seam gas (CSG), conventional oil and gas resources.
Metgasco has established a large CSG reserve of almost 2.1 trillion cubic feet with plenty of potential. Recently announced, its first conventional gas discovery, Kingfisher Field, in November 2009 is in the process of opening a new conventional gas province.
Metgasco is developing gas fired power stations, a gas supply pipeline to customers in south east Australia, and examining potential LNG related export options.
Company:	Nanostart AG
Ticker Symbol & Exchange:	NNS.DE
Investor Relations Contact:	Vanessa Mieschke
Investor Relations Contact Phone:	0049 69 21 93 96 116
Web:	www.nanostart.de
Date of Presentation:	13-Sep
Nanostart, a nanotechnology investment company, announced today that Marco Beckmann, CEO, is scheduled to present at the 2010 Rodman & Renshaw Conference being held in New York. The presentation is scheduled for 04:55 p.m. (EDT) on Monday, September 13, 2010 at the New York Palace Hotel. Marco Beckmann will provide an overview on Nanostart and will highlight current developments of the company and its portfolio. The German based Nanostart invests in young, up-and-coming nanotechnology companies throughout the world. These are companies seeking to commercialize highly innovative products or processes mostly in growth markets such as cleantech, life sciences and healthcare. It currently holds 9 companies from the US, Europe and Asia with groundbreaking technologies in its portfolio.
Company:	NexMed, Inc.
Ticker Symbol & Exchange:	NEXM Nasdaq
Investor Relations Contact:	Paula Schwartz
Investor Relations Contact Phone:	917-322-2216
Web:	http://www.nexmed.com
Date of Presentation:	9/14/2010
Backed by a solid, revenue generating CRO business, NexMed has leveraged the flexibility of its proven NexACT® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. Future growth will be driven primarily through out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies, worldwide. Concurrently, the Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer.
Company:	NPS Pharmaceuticals
Ticker Symbol & Exchange:	NPSP - NASDAQ
Investor Relations Contact:	Susan Mesco
Investor Relations Contact Phone:	908-450-5516
Web:	www.npsp.com
Date of Presentation:	Monday, September 13, 2010
NPS Pharmaceuticals (Nasdaq: NPSP) is developing new treatment options for patients with rare gastrointestinal and endocrine disorders with clear unmet medical needs. The company is currently advancing two Phase 3 registration programs. Teduglutide, a proprietary analog of GLP-2, is being evaluated as GATTEX® in a Phase 3 registration study known as STEPS for intestinal failure associated with short bowel syndrome and is in preclinical development for chemotherapy-induced gastrointestinal mucositis and other pediatric indications. NPSP558 (recombinant parathyroid hormone 1-84 [rDNA origin] injection) is being evaluated in a Phase 3 registration study known as REPLACE as a hormone replacement therapy for hypoparathyroidism. NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates.
Company:	On Track Innovations, Ltd
Ticker Symbol & Exchange:	NASDAQ GM: OTIV
Investor Relations Contact:	Galit Mendelson
Investor Relations Contact Phone:	732-429-1900
Web:	www.otiglobal.com
Date of Presentation:	September 13th, at 11:15am
Established in 1990, OTI designs, develops and markets secure contactless microprocessor-based smart card technology to address the needs of a wide variety of markets. Applications developed by OTI include product solutions for petroleum payment systems, homeland security solutions, electronic passports and IDs, payments, mass transit ticketing, parking and loyalty programs. OTI has a global network of regional offices to market and support its products. The company was awarded the Frost & Sullivan 2005 and 2006 Company of the Year Award in the field of smart cards.
Company:	Peregrine Pharmaceuticals, Inc.
Ticker Symbol & Exchange:	PPHM, Nasdaq
Investor Relations Contact:	Amy Figueroa
Investor Relations Contact Phone:	800-987-8256
Web:	www.peregrineinc.com
Date of Presentation:	13-Sep-10
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.
Company:	Pervasive Software Inc.
Ticker Symbol & Exchange:	NASDAQ: PVSW
Investor Relations Contact:	Randy Jonkers
Investor Relations Contact Phone:	512-231-6090
Web:	http://investor.pervasive.com/
Date of Presentation:	September 15, 2010, 11:40am
With 38 consecutive profitable quarters through June 30, 2010, Pervasive Software (NASDAQ: PVSW since 1997) helps companies get the most out of their data investments through agile, embeddable software and cloud-based services for data management, data integration, B2B exchange and analytics. Pervasive products deliver value to tens of thousands of customers in more than 150 countries with performance, flexibility, reliability and low TCO. Robin Bloor, Chief Research Analyst and President, The Bloor Group, recently listed Pervasive among “10 IT Companies to Watch in 2010” and Pervasive is also on Information Management’s “40 Vendors We’re Watching in 2010.”
Company:	Sino-Gas International Holdings, Inc.
Ticker Symbol & Exchange:	SGAS - OTCBB
Investor Relations Contact:	Richard Cooper,Cooper Global
Investor Relations Contact Phone:	212-317-1400
Web:	www.sino-gas.com
Date of Presentation:	September 15, 2010 - 12:05pm
Sino-Gas International Holdings is a leading developer of natural gas distribution systems in small and medium size cities in China, as well as a distributor of natural gas to residential, commercial and industrial customers in China. The company owns and operates natural gas distribution systems in 35 small and medium size cities and serves approximately 158,500 residential and seven industrial customers. Facilities include approximately 1,040 kilometers of pipeline and delivery networks with a daily capacity of approximately 110,000 cubic meters of natural gas. The Company owns and operates natural gas distribution systems in Beijing, Hebei, Jilin, Jiangsu, Anhui and Yunnan Provinces.
Company:	SOKO Fitness & Spa Group Inc.
Ticker Symbol & Exchange:	OTCBB: SOKF
Investor Relations Contact:	Lee Roth
Investor Relations Contact Phone:	212-481-2050
Web:	www.sokofitness.com
Date of Presentation:	9/14/2010
SOKO Fitness & Spa Group Inc. is a profitable Chinese growth company operating high-end fitness clubs and spa and beauty salon facilities in Northeastern China, as well as Beijing. The Company currently owns and operates seven fitness centers and yoga studios strategically located in Beijing, Shenyang, and Harbin, in addition to twelve beauty salons and spas and one beauty school. Across its three businesses, SOKO provides a unique combination of programs, services and products and is well-positioned to capitalize on the growing market opportunity driven by increased affluence among China’s upper and middle classes. For more information, please visit www.sokofitness.com.
Company:	Top Image Systems (TIS)
Ticker Symbol & Exchange:	TISA
Investor Relations Contact:	Dana Rubin
Investor Relations Contact Phone:	972-3-7679114
Web:	www.topimagesystems.com
Date of Presentation:	Sep 13, 04:30pm
Top Image Systems, Ltd. (NASDAQ: TISA; TASE: TISA), provides inbound document automation software solutions needed to transform information such as invoices, purchase orders and letters entering a business into useful and accessible data, whether it be mobile, electronic, paper or from other sources. Services are delivered through its eFLOW proprietary platform.
In 2009, the company set a goal to increase profitability and margins. Its long-term plan concentrates on profitable regions and activities and, as shown by its six consecutive quarters of positive EBITDA, is succeeding; In Q2, EBITDA increased to $0.62 million, up 32% and EBITDA margins increased to 12% from 8%.
HQ in Israel, the company has branch offices in Germany, UK and Singapore. Customers include Citibank, Standard Chartered Bank, Deutsche Bank , Time Customer Services
Company:	Vringo Inc.
Ticker Symbol & Exchange:	NYSE Amex: VRNG
Investor Relations Contact:	Jon Medved
Investor Relations Contact Phone:	646-525-4319
Web:	www.vringo.com
Date of Presentation:	13-Sep-10
Founded in 2006, Vringo is bringing about the evolution of ringtones. With its award-winning video ringtone application and mobile software platform, Vringo transforms the basic act of making and receiving mobile phone calls into a highly visual, social experience. By installing Vringo’s application, which is compatible with more than 200 handsets, users can create or take video, images and slideshows from virtually anywhere and make it into their personal call signature. Vringo’s patented VringForward™ technology allows you to share your special clip with your friend when you call them. Vringo has launched its service together with several mobile operators and dozens of content partners, and has amassed a library of over 5000 video ringtones. For more information, visit http://ir.vringo.com.
Company:	ZIOPHARM Oncology, Inc.
Ticker Symbol & Exchange:	ZIOP (NASDAQ)
Investor Relations Contact:	Tyler Cook
Investor Relations Contact Phone:	617-259-1982
Web:	www.ziopharm.com
Date of Presentation:	9/13/2010
ZIOPHARM Oncology, Inc. is a biopharmaceutical company that is seeking to develop and commercialize a diverse, portfolio of cancer drugs. Our principal focus is on the development of proprietary small molecule drug candidates that work on validated targets. The goal is to develop intravenous (“IV”) and/or oral forms of administration. We believe this strategy will result in lower-risk and lower-cost development programs with product candidates having a low cost of manufacturing to address changing reimbursement requirements around the world.

About Business Wire

Business Wire, a Berkshire Hathaway company, is utilized by tens of thousands of member companies and organizations worldwide to functionally enhance and communicate investor relations and public relations content to target audiences. As a recognized disclosure service in the United States, Canada and a dozen European countries, Business Wire facilitates the simultaneous flow of market-moving press releases from corporations to financial markets and their audiences, including regulatory authorities, media, investors, financial information systems and consumer news services. Business Wire also handles XBRL tagging, document formatting and regulatory filing into EDGAR, SEDAR, FSA and other systems.

Communications professionals turn to Business Wire to optimize and issue press releases, photos and multimedia to news organizations, journalists, trade publications, search engines, and individuals, with full-text posting to web sites, online services and databases. A range of distribution options enables members to target by geography, industry, news theme and audience demographics.

Founded in 1961, Business Wire has dual headquarters in San Francisco and New York, with 31 bureaus in cities including Los Angeles, Chicago, Boston, Miami, Paris, Frankfurt, London, Brussels, Tokyo, Toronto and Sydney and reciprocal offices throughout the world. Business Wire's patented NX data platform supports XML, XHTML and XBRL code that enhances news release interactivity, social media sharing and search engine optimization. More information about Business Wire and its services is located on its website at www.BusinessWire.com.